ArticleDiscover oncology2025
Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe effectiveness of combination therapies with multiple mechanisms of action in treating advanced hepatocellular carcinoma (HCC) has been highlighted by the observed synergistic antitumor effects. The conversion therapy of hepatic arterial infusion chemotherapy (HAIC) with Atezolizumab and Bevacizumab in HCC has rarely been reported. This case reports a conversion therapy of HAIC combined with Atezolizumab and Bevacizumab for hepatocellular carcinoma. CASE DESCRIPTION: A 58-year-old male patient, with CT diagnosed as a parenchymal liver mass 1 week before admission, suggesting consideration of hepatocellular carcinoma. Further magnetic resonance imaging (MRI) of the liver in our hospital revealed a huge tumor in the right lobe of the liver with large vascular invasion, suggesting a malignant lesion. We performed the HAIC via the implanted arterial infusion port catheter in the right groin region. The patient achieved a complete response after four cycles of FOLFOX-HAIC combined with Atezolizumab and Bevacizumab and then underwent surgical resection of the intrahepatic lesion following conversion therapy, with no recurrence at 17 months after surgery, and this status has continued until the submission of this article. Progression-free survival was 21 months.
conclusionThe combined approach of FOLFOX-HAIC via transarterial infusion port with Atezolizumab and Bevacizumab showed promising results with the potential to improve treatment compliance in certain patients while providing the opportunity for radical surgical resection of advanced HCC. Given these encouraging results, further research on this combination treatment regimen is necessary, and accumulation of further experience is needed to better understand its efficacy and potential wider use in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.